Skip to content

CG Oncology CGON Total Liabilities Assumed in Business Combination

Total Liabilities Assumed in Business Combination at other companies

CG Oncology logo
CG OncologyCGON
$307K
MYR Group logo
MYR GroupMYRG
$970.61M-0.3%
e.l.f. Beauty logo
e.l.f. BeautyELF
$1.26B+159%
Howard Hughes logo
Howard HughesHHH
$7.4B+15.0%
Griffon logo
GriffonGFF
$1.97B-7.4%
American Healthcare REIT logo
American Healthcare REITAHR
$2.08B-3.8%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Reported directly by CG Oncology in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's total liabilities assumed in business combination.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's total liabilities assumed in business combination?
CG Oncology (CGON) reported total liabilities assumed in business combination of $307K in Q1 2026.
What does total liabilities assumed in business combination mean?
This metric represents the total value of obligations and debts acquired by the company as a result of an acquisition or merger transaction. It reflects the liabilities transferred from the acquired entity to the company's balance sheet at the time of the business combination. Monitoring this figure is essential for assessing the impact of inorganic growth strategies on the company's overall leverage and long-term financial risk profile.